I am not the most knowledgeable when it comes to biotechs, not even close.
However I am good at understanding momentum, that is what I am very good at.
HGEN seems to be way ahead of the game in their phase 3 trial. The market cap here is under $1 billion. To compare CYDY who I believe we are ahead of based on the Phase 3 and compassionate use data, has a market cap of over $1.5 billion. $6 was just the start, I fully expect HGEN to head to $10.
We have a Nasdaq Uplisting coming and Phase 3 news in the next 4-8 weeks. There is always the chance the FDA can accelerate our approval as well if the Phase 3 trial is going well.
Personally I like it under $5.
But I am not an expert and this is just my personal thoughts.
There is a lot of noise out there negative about the Compassionate use data. I read everyone's opinions. But all I see is that the JPM crew clearly wanted in and I don't think the Mayo Clinic is known for running a clown show.
I like my chances here. $HGEN #Lenzilumab
GL!
News 
Market Data 
Discover 
